{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:45:33Z","timestamp":1791380733317,"version":"4.3.3"},"reference-count":11,"publisher":"MedWorks Media","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>Alcohol use disorder (AUD) remains a major contributor to the global burden of disease. Extended-release naltrexone (XR-NTX), a \u03bc-opioid receptor antagonist, is a key pharmacological option for maintaining abstinence, though individual treatment response varies substantially. Genetic variability in the \u03bc-opioid receptor gene (OPRM1), particularly rs1799971, may underpin this heterogeneity. Study objective was to evaluate the association between OPRM1 rs1799971 polymorphism and clinical outcomes of XR-NTX therapy in patients with AUD while examining interactions with motivational profiles. In this prospective study, 100 patients with AUD in remission received six monthly intramuscular injections of XR-NTX (380 mg). Genotyping for OPRM1 rs1799971 was performed using real-time allele-specific PCR. Primary outcomes included craving dynamics (PACS), relapse rates, abstinence duration, and treatment adherence over 180 days. Motivation was assessed through structured interviews. The A\/A genotype was associated with longer abstinence (150.6 \u00b1 36.2 days), lower relapse rates (29.2%), greater craving reduction, and higher treatment completion (86.2%) compared to A\/G and G\/G (A\/A vs. A\/G: p = 0.005; A\/A vs. G\/G: p = 0.021). The G allele significantly increased relapse risk (OR = 2.93; 95% CI: 1.48\u22125.79). Intrinsic motivation was associated with better outcomes. A significant genotype-motivation interaction was observed (p = 0.038). No genotype-related differences in adverse event frequency were observed. OPRM1 rs1799971 polymorphism significantly influences the efficacy of XR-NTX in AUD. Carriers of the A\/A genotype derive greater therapeutic benefit, while G allele carriers may require intensified clinical support. Pre-therapeutic OPRM1 genotyping could optimize XR-NTX personalization, with G-allele carriers warranting intensified psychosocial support. Psychopharmacology Bulletin. 2025;55(4):68\u201378.<\/jats:p>","DOI":"10.64719\/pb.4546","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:23:34Z","timestamp":1761045814000},"page":"68-78","source":"Crossref","is-referenced-by-count":3,"title":["OPRM1 rs1799971 Polymorphism Predicts Differential Response to Extended-Release Naltrexone in Alcohol Use Disorder: The Interplay of Genetics and Motivation"],"prefix":"10.64719","volume":"55","author":[{"given":"Valentin","family":"Skryabin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergei","family":"Miroshkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Masyakin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergei","family":"Pozdniakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Ivanchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valery","family":"Shipitsin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Park SH, Kim DJ. Global and regional impacts of alcohol use on public health: emphasis on alcohol policies. Clin Mol Hepatol. 2020;26(4):652\u2013661. doi: 10.3350\/cmh.2020.0160.","DOI":"10.3350\/cmh.2020.0160"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Volkow ND, Blanco C. Substance use disorders: a comprehensive update of classification, epidemiology, neurobiology, clinical aspects, treatment and prevention. World Psychiatry. 2023;22(2):203\u2013229. doi: 10.1002\/wps.21073.","DOI":"10.1002\/wps.21073"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Hansson AC, Gr\u00fcnder G, Hirth N, Noori HR, Spanagel R, Sommer WH. Dopamine and opioid systems adaptation in alcoholism revisited: convergent evidence from positron emission tomography and postmortem studies. Neurosci Biobehav Rev. 2019;106:141\u2013164. doi: 10.1016\/j.neubiorev.2018.09.010.","DOI":"10.1016\/j.neubiorev.2018.09.010"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Thorsell A. The \u03bc-opioid receptor and treatment response to naltrexone. Alcohol Alcohol. 2013;48(4):402\u2013408. doi: 10.1093\/alcalc\/agt030.","DOI":"10.1093\/alcalc\/agt030"},{"key":"ref5","unstructured":"Johnson BA. Naltrexone long-acting formulation in the treatment of alcohol dependence. Ther Clin Risk Manag. 2007;3(5):741\u2013749."},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Garbutt JC, Kranzler HR, O\u2019Malley SS et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA. 2005;293(13):1617\u20131625. doi: 10.1001\/jama.293.13.1617.","DOI":"10.1001\/jama.293.13.1617"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Flannery BA, Volpicelli JR, Pettinati HM. Psychometric properties of the Penn Alcohol Craving Scale. Alcohol Clin Exp Res. 1999;23(8):1289\u20131295.","DOI":"10.1111\/j.1530-0277.1999.tb04349.x"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334:1\u2013100. doi: 10.1111\/j.1600-0447.1987.tb10566.x.","DOI":"10.1111\/j.1600-0447.1987.tb10566.x"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Volpicelli JR, O\u2019Brien CP. A functional polymorphism of the \u03bc-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology. 2003;28(8):1546\u20131552. doi: 10.1038\/sj.npp.1300219.","DOI":"10.1038\/sj.npp.1300219"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Chamorro AJ, Marcos M, Mir\u00f3n-Canelo JA, Pastor I, Gonz\u00e1lez-Sarmiento R, Laso FJ. Association of \u03bc-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis. Addict Biol. 2012;17(3):505\u2013512. doi: 10.1111\/j.1369-1600.2012.00442.x.","DOI":"10.1111\/j.1369-1600.2012.00442.x"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Anton RF, Oroszi G, O\u2019Malley S et al. An evaluation of \u03bc-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry. 2008;65(2):135\u2013144. doi: 10.1001\/archpsyc.65.2.135.","DOI":"10.1001\/archpsyc.65.2.135"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:33:44Z","timestamp":1791315224000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/oprm1-rs1799971-polymorphism-predicts-differential-response-to-extended-release-naltrexone-in-alcohol-use-disorder-the-interplay-of-genetics-and-motivation\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":11,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4546","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}